UKT-04 trial of continuous metronomic low-dose chemotherapy with methotrexate and cyclophosphamide for recurrent glioblastoma.

Al Musella's Comments: (This is his personal views and are not necessarily the views of the Musella Foundation!)

UKT-04 trial of continuous metronomic low-dose chemotherapy with methotrexate and cyclophosphamide for recurrent glioblastoma.

J Neurooncol. 2005 Feb;71(3):295-9. Herrlinger U, Rieger J, Steinbach JP, Nagele T, Dichgans J, Weller M.

Department of General Neurology, Hertie Institute for Clinical Brain Research, University of Tubingen, Hoppe-Seyler-Str. 3, Tubingen, D-72076, Germany, ulrich.herrlinger@uni-tuebingen.de.

Glioblastoma is a highly angiogenic tumor with a dismal prognosis. Continuous oral low-dose chemotherapy with methotrexate (MTX) and cyclophosphamide (CPM) has modest activity in heavily pretreated patients with breast cancer. We explored the efficacy of 100 mg CPM daily and 5 mg MTX twice weekly in relapsed glioblastoma. Ten patients, 22-59 years old, with a Karnofsky score of 50% or higher who had failed at least two chemotherapies were accrued. No toxicity was observed. No patient showed a complete or partial response. Five of 10 patients progressed within 2 months of therapy. Another five patients progressed after 3-4.5 months. The median time to progression was 2.5 months. The median overall survival after start of MTX/CPM was 6.9 months (range 0.5-18.8 months). Since the progression-free survival rate at 6 months was 0%, the trial was prematurely closed. PMID: 15735920 [PubMed - in process]